Vera Therapeutics faces a pivotal moment with Phase 3 data expected soon. Depending on the result, the stock may spike or ...

Studies of the consequences of BAFF overexpression have been complemented by studies investigating the effects of blocking either BAFF or both BAFF and APRIL (a proliferation inducing ligand, also ...

The following reagents were purchased from the indicated manufacturers: rh IL-6, BAFF and SDF-1α from PEPROTECH EC (London, UK); rh TNFα, APRIL, IGF-1, VEGF, neutralizing mouse monoclonal ...

Inc. (Nasdaq: VERA) today announced that on May 5, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 111,750 shares of Class A common ...

Novartis also has an anti-APRIL antibody called zigakibart in phase 3 trials, while Vertex Pharma has a dual antagonist of BAFF and APRIL, povetacicept, which it acquired as part of its takeover ...